{"id":"W2536552580","doi":"10.1007/s11060-016-2288-5","title":"NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma","year":2016,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; NRG Oncology; Wellcome Trust","keywords":"Temozolomide; Irinotecan; Bevacizumab; Glioblastoma; Medicine; Oncology; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Colorectal cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405855,0.00036393,0.002819538,0.0007932696,0.00005881445,0.000007728103,0.0002187738,0.0003089543,0.0003917758],"category_scores_gemma":[0.001863573,0.0001607273,0.0004978157,0.0003662415,0.0004102951,0.0001196335,0.00009079286,0.0005129403,0.0000138537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008639622,"about_ca_system_score_gemma":0.001657958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002082603,"about_ca_topic_score_gemma":0.0003604063,"domain_scores_codex":[0.9955627,0.001191,0.001888273,0.0003619669,0.0005080913,0.0004879096],"domain_scores_gemma":[0.9935281,0.00339352,0.001955546,0.0003558628,0.0003936759,0.000373266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8023304,0.0151867,0.0001420708,0.00002474484,0.0005142845,0.0105847,0.0004974537,0.000005025836,0.0394954,0.00002701902,0.00159966,0.1295926],"study_design_scores_gemma":[0.7418507,0.2065544,0.0001645583,0.000316248,0.0008138426,0.005326939,0.0001040133,0.00001910305,0.01244719,0.00006182431,0.03220113,0.0001400896],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803932,0.000268276,0.00003480446,0.01610326,0.001016026,0.001692347,0.00001448587,0.00001755079,0.0004601051],"genre_scores_gemma":[0.9972952,0.0007945006,0.0006894285,0.0005209458,0.0004457993,0.0001240061,0.000001129068,0.00005083004,0.00007815396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1913677,"threshold_uncertainty_score":0.6554271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03050901912674331,"score_gpt":0.350022182008827,"score_spread":0.3195131628820837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}